Eli Lilly Announces FDA Breakthrough Therapy Designation For Olomorasib Monotherapy In Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer, Second Such Designation For Drug

뉴스 본문을 불러오고 있어요.

Eli Lilly Announces FDA Breakthrough Therapy Designation For Olomorasib Monotherapy In Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer, Second Such Designation For Drug | 웨이프 WAPE

Eli Lilly Announces FDA Breakthrough Therapy Designation For Olomorasib Monotherapy In Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer, Second Such Designation For Drug

기사 요약

관련 종목

댓글 —